Key result
Higher monocyte-to-HDL ratio links to ~35% higher odds of endothelial dysfunction in type 2 diabetes.
Why the study?
The relationship between monocyte-to-HDL cholesterol ratio (MHR) and endothelial function in patients with type 2 diabetes was not well established.
Is the monocyte-to-HDL cholesterol ratio associated with endothelial dysfunction in patients with type 2 diabetes?
Cross-Sectional (n=243)
Is the monocyte-to-HDL cholesterol ratio associated with endothelial dysfunction in patients with type 2 diabetes?
Odds Ratio: 1.35 (95% CI 1.08–1.7)
p-value: p=<0.05
The monocyte-to-HDL cholesterol ratio is independently associated with endothelial dysfunction in patients with type 2 diabetes and may serve as a novel biomarker for vascular health.
MHR may mark endothelial dysfunction in T2DM; leaves open its added value for risk stratification or therapy guidance.
Aims. To explore the relationship between monocyte‐to‐HDL cholesterol ratio (MHR) and endothelial function in patients with type 2 diabetes (T2DM). Methods. 243 patients diagnosed with T2DM were enrolled in this cross‐sectional study. Patients were divided into two groups by flow‐mediated dilation (FMD) quintile as nonendothelial dysfunction (FMD ≥ 6.4%) and endothelial dysfunction (FMD < 6.4%). The relationship between MHR and FMD was analyzed using Spearman’s correlation, partial correlation, and multiple logistic regression analysis. ROC curve was fitted to evaluate the ability of MHR to predict endothelial dysfunction. Results. Endothelial dysfunction was present in 193 (79%) patients. Patients with endothelial dysfunction had higher MHR (p < 0.05) than those without endothelial dysfunction. Furthermore, MHR had a significantly positive correlation with endothelial dysfunction (r = 0.17, p < 0.05), and the positive association persisted even after controlling for confounding factors (r = 0.14, p < 0.05). Logistic regression showed that MHR was an independent contributor for endothelial dysfunction (OR: 1.35 (1.08, 1.70), p < 0.05) and the risk of endothelial dysfunction increases by 61% with each standard deviation increase in MHR (OR: 1.61 (1.12, 2.30), p < 0.05) (model 1). After adjusting for sex, age, BMI, disease course, hypertension, smoking, and drinking (model 2) as well as HbA1c, HOMA‐IR, C‐reactive protein, and TG (model 3), similar results were obtained. In ROC analysis, the area of under the ROC curve (AUC) for MHR was 0.60 (95% CI 0.52‐0.69, p < 0.05). Conclusion. MHR was independently associated with endothelial dysfunction in T2DM patients. It could be a new biomarker for vascular endothelial function assessment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a cross-sectional in Type 2 diabetes (n=243). Monocyte-to-HDL cholesterol ratio (MHR) was evaluated on Endothelial dysfunction (flow-mediated dilation < 6.4%) (OR 1.35, 95% CI 1.08-1.70, p=<0.05). Higher monocyte-to-HDL cholesterol ratio was independently associated with endothelial dysfunction in patients with type 2 diabetes (OR 1.35; 95% CI 1.08-1.70; p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: